Biov Inc. Discusses Innovative Therapies for Neurological Disorders and Long COVID

Biov Inc.'s Innovative Therapies

• 💡 Biov Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurological and neurodegenerative disorders.
• 🔬 Their primary molecule, bzyum, targets inflammation, which is believed to be a key factor in conditions like Parkinson's.
• 🧠 By aiming to reset the inflammatory balance, bzyum seeks to restore cellular energy, improve neuron function, and potentially enhance movement, cognition, and sleep in patients.

Addressing Long COVID Symptoms

• ⚠️ Research indicates that Long COVID also involves inflammatory processes, specifically changes in cytokines and other molecules.
• ⚡ Biov Inc. is investigating bzyum's potential to alleviate Long COVID symptoms such as brain fog and reduced energy levels.
• 📊 This research is supported by a grant from the Department of Defense, focusing on correcting inflammatory imbalances to improve cognitive function and productivity.

Department of Defense Grant

• 💰 Biov Inc. has been awarded $13.1 million from the Department of Defense through a competitive grant process.
• ✅ The grant was awarded based on Biov's unique mechanism of action in addressing inflammation.
• 🚀 The company is preparing to initiate studies at selected sites, having shipped the drug candidate and awaiting final approval to begin.